Blue Water Ventures International, Inc. (BWVI)
Chart Events
Performance Outlook
| Previous Close | 0.0705 |
| Open | 0.0800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0655 - 0.0800 |
| 52 Week Range | 0.0540 - 0.1893 |
| Volume | |
| Avg. Volume | 33,923 |
| Market Cap | 17.971M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BWVI
Related Research
- BLUE WATER VENTURES INTL INCAnalyst Report: PPG Industries, Inc.PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.RatingFair ValueEconomic Moat2 days agoMorningstar
- ACCESSWIRE
Psycheceutical Bioscience Launches Wefunder Crowdfunding Campaign for Safer Psychedelic Dosing
Investors are invited to support Psycheceutical's mission to revolutionize psychedelic medicines by taking part in the company's Wefunder Community Round.Community Crowdfunding Campaign now live for all levels of investors"Original Shark" Kevin Harrington, ...
- ACCESSWIRE
Psycheceutical Announces Successful First Cohort Dosing; Moves to Dose Escalation in Phase I Trial of NeuroDirect Ketamine for PTSD
Psycheceutical Bioscience, Inc. ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the completion of dosing of the first cohort of subjects in a Phase I clinical trial of its patented NeuroDirect™ topical ketamine formulation for the treatment of Post Traumatic Stress Disorder (PTSD).
- ACCESSWIRE
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Psycheceutical Bioscience, Inc. ("Psycheceutical'' or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that its auditors RBSM LLP have completed a PCAOB audit of the company's financial statements for the periods ending December 31, 2022 and 2021.
